Maker Of Hepatitis Drugs Goes Crazy After Merck Agrees To Buy The Company For $3.85 Billion
Advertisement
REUTERS/David McNew
Advertisement
The deal values Idenix $24.50 per share; shares of Idenix closed at $7.23 on Friday.
Idenix is engaged in the development of hepatitis C drugs, and according to the merger announcement, Idenix has three hepatitis C drugs in clinical development.
Gilead Sciences, which has seen shares gain more than 120% since the beginning of 2013, received FDA approval for its hepatitis C drug Sovaldi in December. Shares of Gilead are down about 1.5% in pre-market trading.
Merck and Idenix expect the deal to close in the third quarter. In pre-market trading Merck is down 0.7%.
Advertisement
Advertisement
- Singapore Airlines was ordered to pay a couple compensation for 'mental agony' after they complained their business-class seats didn't automatically recline
- Welcome to the white-collar recession
- A software engineer shares the résumé he's used since college that got him a $500,000 job at Meta — plus offers at TikTok and LinkedIn
- People intolerant of other religions are more likely to reject science, study asserts
- 7 reasons why cucumber can be your summer weight loss friend
- 8 refreshing kulfis you must try this summer
- Adani Enterprises Q4 net falls 37%; incubating businesses show strong momentum
- India, New Zealand hold Joint Trade Committee meeting to deepen relations